Anavex Life Sciences Corp. announced the latest findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease, presented at the 2025 Alzheimer's Association International Conference (AAIC). Data from the ATTENTION-AD open-label extension (OLE) Phase IIb/III trial showed continued benefit for blarcamesine-treated patients through up to four years.
In the GWAS-identified ABCLEAR2 population, which represents approximately 71.7% of the global population, blarcamesine demonstrated further improved cognition (ADAS-Cog13 difference −5.43, P = 0.0035) and function (ADCS-ADL difference +9.50, P < 0.0001) at Week 192. This clinical precision medicine data indicates up to 84.6 Weeks (19.5 Months) of ‘time saved’ in disease progression, a clinically meaningful measure directly related to a patient's daily life.
The presentation also featured mechanistic confirmation that blarcamesine restores impaired autophagy through SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level. This upstream mechanism, combined with the favorable safety profile and no treatment-related deaths, reinforces blarcamesine's potential to provide sustained clinically meaningful benefits to patients with early Alzheimer’s disease over the long-term.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.